Literature DB >> 12153810

Diffuse iris melanoma: a report of 25 cases.

Hakan Demirci1, Carol L Shields, Jerry A Shields, Ralph C Eagle, Santosh G Honavar.   

Abstract

BACKGROUND: Diffuse iris melanoma is a rare variant of iris melanoma that has a flat growth pattern and often presents as unilateral hyperchromic heterochromia and glaucoma. There have been no large clinical reports of diffuse iris melanoma.
DESIGN: Single-center retrospective case series. PARTICIPANTS: Twenty-five consecutive patients with diffuse iris melanoma.
METHODS: A review of the clinical features, management, histopathologic analysis, and prognosis was performed. MAIN OUTCOME MEASURES: Clinical features, histopathologic features, management, and prognosis.
RESULTS: At the time of diagnosis, the mean patient age was 49 years. The initial complaint was unilateral darker eye color in 13 cases (52%) and blurred vision in 6 (24%). Six patients (24%) were symptom free. On presentation elsewhere, the initial diagnosis was iris melanoma or nevus in 11 cases (44%) and glaucoma in 14 (56%), 8 (32%) of whom had prior laser or surgical treatment for glaucoma. The 25 patients were observed for a mean of 30 months before the diagnosis of melanoma was suspected and referral to our center for evaluation. The mean intraocular pressure at referral was 36 mmHg, and the mean number of clock hours involved by tumor was 11. Heterochromia iridis was present in all 25 cases (100%), corectopia in 23 (92%), and ectropion iridis in 21 (84%). Associated findings included unilateral cataract in 8 (32%), a prominent episcleral (sentinel) vessel in 7 (28%), and anterior chamber inflammation in 5 (20%), and synechiae (anterior or posterior) in none. The tumor was managed by enucleation in 22 cases (88%) and by plaque brachytherapy in 3 (12%). Five cases (20%) were classified as spindle melanoma, 17 (68%) as mixed cell type, and 3 (12%) as epithelioid cell type. Therefore, histopathologic examination showed that 80% of cases contained epithelioid cells. All 22 enucleated cases were found to have tumor invasion in the trabecular meshwork. Tumor invasion of Schlemm's canal was found in 18 (82%), minor pars plicata in 12 (55%), and episclera in 7 cases (28%). Of seven cases with episcleral invasion, four underwent surgical treatment for glaucoma. Excluding one recent case, the patients were observed for a mean of 78 months. Liver metastasis developed in 3 cases (13%).
CONCLUSIONS: Diffuse iris melanoma is a serious ocular condition that causes unilateral hyperchromic heterochromia and secondary glaucoma, often leading to a delay in diagnosis. Local invasion of adjacent ocular structures is common, and distant metastasis occurs in 13% of cases at mean follow-up of 78 months.

Entities:  

Mesh:

Year:  2002        PMID: 12153810     DOI: 10.1016/s0161-6420(02)01104-1

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  17 in total

Review 1.  [New treatment options for iridociliary tumors].

Authors:  J M Mor; K R Koch; V Kakkassery; C Cursiefen; L M Heindl
Journal:  Ophthalmologe       Date:  2019-04       Impact factor: 1.059

Review 2.  Don't it make my blue eyes brown: heterochromia and other abnormalities of the iris.

Authors:  I G Rennie
Journal:  Eye (Lond)       Date:  2011-10-07       Impact factor: 3.775

3.  [Iridal color changing in ocular masquerade syndrome].

Authors:  S Waibel; K Pillunat; L Pillunat
Journal:  Ophthalmologe       Date:  2018-06       Impact factor: 1.059

Review 4.  Uveal melanoma: relatively rare but deadly cancer.

Authors:  S Kaliki; C L Shields
Journal:  Eye (Lond)       Date:  2016-12-02       Impact factor: 3.775

5.  Diffuse iris melanoma: Report of a case with review of the literature.

Authors:  Simon E Skalicky; Michael Giblin; R Max Conway
Journal:  Clin Ophthalmol       Date:  2007-09

6.  Proton beam therapy for presumed and confirmed iris melanomas: a review of 36 cases.

Authors:  Ahmed Rahmi; Hamid Mammar; Juliette Thariat; Gaelle Angellier; Joel Herault; Pierre Chauvel; Laurent Kodjikian; Philippe Denis; Jean Daniel Grange
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-07-20       Impact factor: 3.117

Review 7.  Diffuse Iris Melanoma: Conservative Treatment with Proton Beam Therapy after Limbal Stem Cell Preservation or Enucleation?

Authors:  Alice Leblanc; Livia Lumbroso-Le Rouic; Laurence Desjardins; Rémi Dendale; Nathalie Cassoux
Journal:  Ocul Oncol Pathol       Date:  2019-03-20

8.  [Relative contraindication of latanoprost in iris tumors with secondary glaucoma].

Authors:  S J Fröhlich; A J Mueller; A Kampik
Journal:  Ophthalmologe       Date:  2003-08       Impact factor: 1.059

Review 9.  Review of cystic and solid tumors of the iris.

Authors:  Carol L Shields; Patrick W Shields; Janet Manalac; Chaisiri Jumroendararasame; Jerry A Shields
Journal:  Oman J Ophthalmol       Date:  2013-09

10.  A case of unilateral sectoral iris heterochromia in an infant with Beckwith-Wiedemann syndrome.

Authors:  Maram Alnefaie; Mona Jefri; Fayqah Almahmoudi
Journal:  Am J Ophthalmol Case Rep       Date:  2021-06-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.